XML 93 R80.htm IDEA: XBRL DOCUMENT
v3.22.4

INTANGIBLE ASSETS AND GOODWILL - Narrative (Details) |  |  |  |  |  |  |  | 2 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | 24 Months Ended |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Oct. 01, 2022 USD ($) | Oct. 01, 2021 USD ($) | Jun. 30, 2021 USD ($) | Mar. 31, 2021 USD ($) | Oct. 01, 2020 USD ($) | Jun. 30, 2020 USD ($) | Mar. 31, 2020 USD ($) | Jun. 30, 2022 USD ($) reporting_unit | Dec. 31, 2022 USD ($) | Sep. 30, 2022 USD ($) | Jun. 30, 2022 USD ($) | Mar. 31, 2022 USD ($) reporting_unit | Sep. 30, 2022 USD ($) | Sep. 30, 2021 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2019 USD ($)
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Asset impairments, including loss on assets held for sale |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 15,000,000 | $ 234,000,000 | $ 114,000,000 |  |
Impairment of Intangible Asset, Finite Lived, Statement of Income or Comprehensive Income, Extensible Enumeration, Not Disclosed Flag |  |  |  |  |  |  |  |  |  |  |  |  |  |  | impairments | impairments |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 8,124,000,000 | $ 8,434,000,000 | 8,027,000,000 |  |
Finite-lived intangible assets |  |  |  |  |  |  |  |  | $ 4,102,000,000 |  |  |  |  |  | 4,102,000,000 | 5,250,000,000 |  | $ 5,250,000,000 |
Goodwill impairments |  |  | $ 0 | $ 0 |  |  |  |  |  |  |  |  |  |  | 824,000,000 | 469,000,000 |  |  |
Percentage of fair value in excess of carrying value |  |  | 45.00% | 40.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill |  |  |  |  |  |  |  |  | 11,547,000,000 |  |  |  |  |  | 11,547,000,000 | 12,457,000,000 | 13,044,000,000 | 12,457,000,000 | $ 13,126,000,000
Salix |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,090,000,000 | 2,074,000,000 | 1,904,000,000 |  |
Goodwill impairments |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 |  |  |
Goodwill |  |  |  |  |  |  |  |  | 3,159,000,000 |  |  |  |  |  | 3,159,000,000 | 3,159,000,000 | 3,159,000,000 | 3,159,000,000 | 3,159,000,000
Ortho Dermatologics |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill impairments |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 469,000,000 |  |  |
Number of reporting units | reporting_unit |  |  |  |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |  |
Goodwill |  |  |  |  |  |  |  |  | 0 |  |  |  |  |  | 0 | 798,000,000 | 1,267,000,000 | 798,000,000 | $ 1,267,000,000
Xifaxan Branded Products |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Impairment of intangible assets |  |  |  |  |  |  |  |  | 0 | $ 0 |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,216,000,000 | $ 1,194,000,000 |  |  |  |  |
Finite-lived intangible assets |  |  |  |  |  |  |  |  | 2,693,000,000 |  |  |  |  |  | $ 2,693,000,000 |  |  |  |
Finite lived intangible assets, useful life |  |  |  |  |  |  |  |  |  |  |  |  | 60 months |  |  |  |  |  |
Xifaxan Branded Products | Revenue from Contract with Customer, Segment Benchmark | Product Concentration Risk | Salix |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Concentration risk, percentage |  |  |  |  |  |  |  |  |  | 80.00% |  |  | 80.00% |  | 80.00% |  |  |  |
Bausch + Lomb |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of reporting units | reporting_unit |  |  |  |  |  |  |  | 3 |  |  |  |  |  |  |  |  |  |  |
Ortho Dermatologics Reporting Unit |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill impairments |  | $ 0 |  | $ 469,000,000 | $ 0 | $ 0 | $ 0 |  |  | $ 119,000,000 | $ 83,000,000 | $ 0 |  |  |  |  |  |  |
Reporting unit, impairment test, long-term growth rates |  | 1.00% |  | 1.00% | 2.00% |  |  | 1.00% |  | 1.00% | 1.00% | 1.00% | 1.00% |  |  |  |  |  |
Reporting unit, impairment test, estimated cash flows, discount rate |  | 9.00% |  |  |  |  |  | 10.00% |  | 10.50% | 10.00% | 9.00% | 10.50% |  |  |  |  |  |
Percentage of fair value in excess of carrying value |  | 10.00% |  |  | 10.00% |  |  |  |  |  |  | 2.00% |  |  |  |  |  |  |
Reporting unit, impairment test, estimated cash flows, change in discount rate |  |  |  |  |  |  |  | 1.00% |  |  | 1.00% |  |  |  |  |  |  |  |
Goodwill |  |  |  |  |  |  |  |  |  | $ 480,000,000 |  |  | $ 480,000,000 |  |  |  |  |  |
Reporting Units Excluding Ortho Dermatologics |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill impairments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |
Vision Care, Surgical And Ophthalmic Reporting Units | Bausch + Lomb |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill impairments |  |  |  |  |  |  |  | $ 0 | $ 0 |  |  |  |  |  |  |  |  |  |
Percentage of fair value in excess of carrying value |  |  |  |  |  |  |  | 25.00% | 25.00% |  | 25.00% |  |  |  | 25.00% |  |  |  |
Salix Reporting Unit |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill impairments |  |  |  |  |  |  |  |  |  | $ 0 |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, long-term growth rates |  |  |  |  |  |  |  |  |  | 2.50% |  |  | 2.50% |  |  |  |  |  |
Percentage of fair value in excess of carrying value |  |  |  |  |  |  |  |  |  | 5.00% |  |  | 5.00% |  |  |  |  |  |
Neurology and Other Reporting Unit |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill impairments | $ 622,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, long-term growth rates |  |  |  |  |  |  |  |  | (2.50%) |  |  |  |  |  | (2.50%) |  |  |  |
Reporting unit, impairment test, estimated cash flows, discount rate |  |  |  |  |  |  |  |  | 10.25% |  |  |  |  |  | 10.25% |  |  |  |
Goodwill |  |  |  |  |  |  |  |  | $ 1,439,000,000 |  |  |  |  |  | $ 1,439,000,000 |  |  |  |
Surgical Reporting Unit |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accumulated goodwill impairment charges to date |  |  |  |  |  |  |  |  | $ 5,004,000,000 |  |  |  |  |  | $ 5,004,000,000 |  |  |  |
Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, long-term growth rates |  |  | 2.00% | 1.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, estimated cash flows, discount rate |  |  | 7.00% | 11.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Minimum | Ortho Dermatologics Reporting Unit |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, estimated cash flows, discount rate |  |  |  | 9.00% | 9.50% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Minimum | Vision Care, Surgical And Ophthalmic Reporting Units | Bausch + Lomb |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, long-term growth rates |  |  |  |  |  |  |  | 2.00% | 2.00% |  | 2.00% |  |  |  | 2.00% |  |  |  |
Reporting unit, impairment test, estimated cash flows, discount rate |  |  |  |  |  |  |  | 9.00% | 9.50% |  | 9.00% |  |  |  | 9.50% |  |  |  |
Minimum | Salix Reporting Unit |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, estimated cash flows, discount rate |  |  |  |  |  |  |  |  |  | 9.75% |  |  | 9.75% |  |  |  |  |  |
Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, long-term growth rates |  |  | 3.00% | 3.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, estimated cash flows, discount rate |  |  | 10.00% | 12.25% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum | Ortho Dermatologics Reporting Unit |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, estimated cash flows, discount rate |  |  |  | 10.00% | 9.75% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum | Vision Care, Surgical And Ophthalmic Reporting Units | Bausch + Lomb |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, long-term growth rates |  |  |  |  |  |  |  | 3.00% | 3.00% |  | 3.00% |  |  |  | 3.00% |  |  |  |
Reporting unit, impairment test, estimated cash flows, discount rate |  |  |  |  |  |  |  | 11.50% | 12.25% |  | 11.50% |  |  |  | 12.25% |  |  |  |
Maximum | Salix Reporting Unit |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reporting unit, impairment test, estimated cash flows, discount rate |  |  |  |  |  |  |  |  |  | 10.00% |  |  | 10.00% |  |  |  |  |  |
Acquired IPR&D |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Impairment of indefinite-lived intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,000,000 |  |
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Amoun |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Impairment of intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 88,000,000 |  |  |
Impairment of long-lived assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 26,000,000 |  | 210,000,000 |
Held For Sale | A Certain International Business |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Impairment of long-lived assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 96,000,000 |  |
Product brands |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Impairment of intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 10,000,000 | 105,000,000 | 16,000,000 |  |
Finite-lived intangible assets |  |  |  |  |  |  |  |  | $ 3,644,000,000 |  |  |  |  |  | $ 3,644,000,000 | 4,673,000,000 |  | $ 4,673,000,000 |
Finite lived intangible assets, useful life |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5 years |  |  |  |
Product brands | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite lived intangible assets, useful life |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 year |  |  |  |
Product brands | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite lived intangible assets, useful life |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 20 years |  |  |  |
Discontinued Product Lines |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Impairment of intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 5,000,000 | 23,000,000 | $ 1,000,000 |  |
Unutilized IT Infrastructure Improvement Project |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Impairment of intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 18,000,000 |  |  |

X
- Definition Impairment Of Intangible Asset, Finite Lived, Statement Of Income Or Comprehensive Income, Extensible Enumeration, Not Disclosed Flag + References No definition available. + Details
Name: | bhc_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag
Namespace Prefix: | bhc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate + References No definition available. + Details
Name: | bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
Namespace Prefix: | bhc_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Reporting Unit, Impairment Test, Estimated Cash Flows, Increase (Decrease) In Discount Rate + References No definition available. + Details
Name: | bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate
Namespace Prefix: | bhc_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Reporting Unit, Impairment Test, Long-Term Growth Rate + References No definition available. + Details
Name: | bhc_ReportingUnitImpairmentTestLongTermGrowthRate
Namespace Prefix: | bhc_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -URI https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228 + Details
Name: | us-gaap_AssetImpairmentCharges
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 926 -SubTopic 20 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (h) -URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 55 -Paragraph 24 -URI https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 852 -SubTopic 10 -Section 55 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 45 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_Goodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (h) -URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 55 -Paragraph 24 -URI https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 + Details
Name: | us-gaap_GoodwillImpairedAccumulatedImpairmentLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 2 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 45 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 55 -Paragraph 24 -URI https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 + Details
Name: | us-gaap_GoodwillImpairmentLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275 + Details
Name: | us-gaap_ImpairmentOfIntangibleAssetsFinitelived
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585 + Details
Name: | us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 15 -URI https://asc.fasb.org/extlink&oid=126905981&loc=d3e2611-110228 + Details
Name: | us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment. + References No definition available. + Details
Name: | us-gaap_NumberOfReportingUnits
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of fair value of reporting unit in excess of carrying amount. + References No definition available. + Details
Name: | us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_XifaxanBrandedProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=bhc_BauschLombMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=bhc_OrthoDermatologicsReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=bhc_ReportingUnitsExcludingOrthoDermatologicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=bhc_SalixReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=bhc_NeurologyAndOtherReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=bhc_SurgicalReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=bhc_AcquiredInProcessResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_AmounPharmaceuticalCompanySAEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_ACertainInternationalBusinessMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_DiscontinuedProductLinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_UnutilizedITInfrastructureImprovementProjectMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |